Iambic Therapeutics and Jazz Pharmaceuticals Announce Research Collaboration to Evaluate IAM1363 and Zanidatamab Combination in HER2-Positive Breast Cancer SAN DIEGO, Calif., October 22, 2025 – Iambic Therapeutics, a clinical-stage life science and technology company pioneering the use of artificial intelligence…
Enamine Plays Key Role in Discovery of Promising Broad-Spectrum Coronavirus Antiviral Enamine, a leading chemistry and R&D services company, has announced its pivotal contribution to the discovery of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. This milestone was achieved through…
Bayer to Present Late-Breaking OCEANIC-STROKE Data at World Stroke Congress 2025 Bayer will present methods and baseline characteristic data from its global Phase III OCEANIC-STROKE study in a late-breaking presentation at the 17th World Stroke Congress (WSC 2025). The Congress…
a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society…
a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at IDWeek 2025™ in Atlanta, Ga., by researchers from Columbia University Irving Medical Center show metagenomic sequencing that detects both RNA and DNA pathogens, available through Delve…
a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicines, today announced the presentation of two-year data from the FALCON study, a prospective natural history study in people with Autosomal Dominant Optic Atrophy (ADOA)…
Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced clinical data for IAM1363, a brain-penetrant HER2 small-molecule tyrosine kinase inhibitor (TKI), which showed anti-tumor activity in heavily pretreated…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for…
the AI precision oncology company behind the Polaris™ platform, today announced its selection for the Memorial Sloan Kettering (MSK) iHub Challenge 2025 Cohort program. This engagement will provide StratifAI with access to MSK’s extensive clinical datasets and the opportunity to…
(Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met…